{"product_id":"globalcordbloodcorp-pestle-analysis","title":"Global Cord Blood PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, social attitudes, and technological advances are redefining Global Cord Blood’s market position; our concise PESTLE highlights the key external risks and opportunities you need to act on. Buy the full PESTLE for a complete, editable report with strategic recommendations—ideal for investors, advisors, and executives seeking an immediate edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Healthcare Strategic Alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Chinese 14th Five-Year Plan and Healthy China 2030 roadmap keep biotech and regenerative medicine as priorities through 2025, with national R\u0026amp;D funding hitting RMB 2.4 trillion in 2024; this regulatory alignment supports cord blood banking as critical healthcare infrastructure. Global Cord Blood Corporation must sustain close engagement with National Health Commission and provincial bureaus to align services with reimbursement pilots and licensing updates affecting \u0026gt;400 licensed cord blood banks nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Regulatory Scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company, operating heavily in China with past US\/HK listings, faces intensified scrutiny from Chinese regulators and Western agencies; since 2023 cross-border audit delistments rose 18%, and 2024 rules tightened on data transfers affecting biotech firms handling genetic data. Escalating US-China trade and data-security tensions have prompted sudden compliance shifts—investors should track changes that could limit access to international capital markets or force restructuring of corporate listings and reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Licensing Monopolies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe political landscape in China for cord blood banking is defined by a strict licensing system where typically only one license is issued per province; as of 2024 China has ~31 provincial-level jurisdictions, creating high entry barriers.\u003c\/p\u003e\n\u003cp\u003eGlobal Cord Blood Corporation benefits as a protected operator in its authorized provinces, yielding stable market share and predictable revenue streams—company reported HKD 1.12 billion revenue in FY2023.\u003c\/p\u003e\n\u003cp\u003eExpansion requires political maneuvering and acquisition of provincial permits from health bureaus, making growth contingent on regulatory approvals and local government relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Population Incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChina's shift to a three-child policy and subsidies aims to counter a 2023 TFR of about 1.08 and an annual births drop to ~9.3 million in 2023, potentially enlarging the cord blood addressable market if birth rates recover.\u003c\/p\u003e\n\u003cp\u003ePolicy efficacy is uncertain; analysts project births could rise modestly, affecting long-term subscriber growth and revenue forecasts for cord blood firms tied to demographic trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 births ~9.3M; TFR ~1.08\u003c\/li\u003e\n\u003cli\u003eThree-child policy + subsidies target fertility recovery\u003c\/li\u003e\n\u003cli\u003eSubscriber volume growth depends on policy success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Driven Biotech Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe state provides subsidies and tax breaks—China increased R\u0026amp;D tax incentives to 75% super-deduction in 2023 and allocated RMB 30 billion to biotech funds in 2024—benefiting Global Cord Blood Corporation by lowering effective R\u0026amp;D costs and enabling facility upgrades.\u003c\/p\u003e\n\u003cp\u003eContinued support hinges on demonstrable contributions to national medical-tech self-sufficiency, with the company required to show local production capacity and IP generation to retain preferential treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D tax super-deduction 75% (2023)\u003c\/li\u003e\n\u003cli\u003eRMB 30B biotech funding (2024)\u003c\/li\u003e\n\u003cli\u003eSupport tied to local manufacturing\/IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina pours RMB2.4T into R\u0026amp;D, super-deductions boost Global Cord Blood amid tight licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical support (14th Five-Year, Healthy China 2030) channels RMB 2.4T R\u0026amp;D funding (2024) and RMB 30B biotech funds (2024); 75% R\u0026amp;D super-deduction (2023) lowers costs for Global Cord Blood. Strict provincial one-license regime (~31 provinces) creates high barriers but protects incumbent market share (HKD 1.12B revenue FY2023). Demographics: 2023 births ~9.3M; TFR ~1.08.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D funding 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 2.4T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funds 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 30B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D super-deduction\u003c\/td\u003e\n\u003ctd\u003e75% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvinces\/licenses\u003c\/td\u003e\n\u003ctd\u003e~31 (one per province)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Cord Blood rev\u003c\/td\u003e\n\u003ctd\u003eHKD 1.12B (FY2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 births \/ TFR\u003c\/td\u003e\n\u003ctd\u003e~9.3M \/ 1.08\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact the Global Cord Blood sector across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and region-specific regulatory context to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, PESTLE-organized brief that distills regulatory, economic, social, technological, environmental, and legal factors impacting the global cord blood sector for quick inclusion in presentations or strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiddle-Class Disposable Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand for private cord blood storage in China closely tracks urban middle-class disposable income, which rose 5.0% in 2024 to about CNY 74,000 per capita in cities; higher-income families increasingly pay for stem cell preservation as health insurance for children. Metropolitan economic stability—Beijing, Shanghai, Guangdong contributing ~45% of national GDP—sustains penetration rates critical to providers' revenue growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising public and private healthcare infrastructure investment in China—estimated at RMB 1.2 trillion in 2024 with a 7% CAGR since 2020—strengthens the ecosystem for cord blood services by upgrading hospitals and adding ~8,000 specialized clinics nationwide. Better-equipped facilities increase partnership opportunities for cord blood collection, supporting network expansion and boosting service accessibility, potentially raising addressable birth-capture rates by 10–15% in key urban centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Storage Cost Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe revenue model relies on storage fees spanning 18+ years, making revenues highly sensitive to domestic inflation; US CPI rose 3.4% in 2024, implying real margin erosion unless fees are indexed. Rising electricity and liquid nitrogen costs—US industrial electricity up ~6% 2023–24 and LN2 spot volatility of ±10%—plus skilled technician wages (healthcare lab pay up ~5% in 2024) can compress margins. In contrast, deflationary pressure could lower upfront processing costs, boosting uptake among price-sensitive expectant parents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemographic Economic Impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChina's working-age population fell by 2.6% between 2015–2023, contributing to a 2023 birth rate of 6.7 per 1,000 and just 9.56 million births—the lowest since 1961; fewer births shrink immediate cord-blood subscriber pools.\u003c\/p\u003e\n\u003cp\u003eSimultaneously, China had 20% of its population aged 60+ in 2023 (~300 million), driving higher prevalence of age-related disorders and increasing projected demand for stem-cell therapies and biobanking services.\u003c\/p\u003e\n\u003cp\u003eThe company must split marketing spend between pediatric cord‑blood collection and long‑term positioning for geriatric regenerative therapies, optimizing LTV against shrinking acquisition cohorts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 births: 9.56 million → smaller immediate subscriber base\u003c\/li\u003e\n\u003cli\u003e60+ population ~300 million (20% of population) → rising therapy demand\u003c\/li\u003e\n\u003cli\u003eStrategy: dual-target marketing; prioritize LTV and long‑term service pipelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Access and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpeconomic conditions in including tighter global liquidity and a us federal funds rate around compress valuations raise debt costs limiting cord bloods ability to fund acquisitions or upgrades without diluting equity.\u003e\n\u003cphigh market volatility and elevated bond yields push up borrowing spreads equity issuance may underperform term loan margins rose bps in for middle-market deals.\u003e\n\u003cpmaintaining cash reserves and near-term liquidity\u003e6–12 months of operating cash) is critical to sustain capex in storage technology and absorb cyclical revenue shocks.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher interest rates: increases cost of debt, tightens acquisition financing\u003c\/li\u003e\n\u003cli\u003eMarket volatility: reduces attractiveness of equity raises\u003c\/li\u003e\n\u003cli\u003eCash buffer (\u0026gt;6–12 months ops): vital for capex and downturn resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmaintaining\u003e\u003c\/phigh\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising incomes and ageing population drive healthcare demand; higher rates tighten cash needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic drivers: urban disposable income (+5.0% in 2024 to CNY ~74,000) boosts private storage demand; 2023 births 9.56M shrink addressable pool while 60+ ~300M increases long‑term therapy demand; China healthcare capex ~RMB 1.2T in 2024 (7% CAGR) expands collection sites; global rates (US fed funds ~5.25–5.50% in 2024) raise borrowing costs, requiring 6–12 months cash buffer.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2023–24)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBirths\u003c\/td\u003e\n\u003ctd\u003e9.56M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e60+ population\u003c\/td\u003e\n\u003ctd\u003e~300M (20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrban per capita income\u003c\/td\u003e\n\u003ctd\u003eCNY ~74,000 (+5.0%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare investment\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS fed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGlobal Cord Blood PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Global Cord Blood PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the layout, content, and analysis visible in this preview are the final file you’ll be able to download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751862808953,"sku":"globalcordbloodcorp-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/globalcordbloodcorp-pestle-analysis.png?v=1772235479","url":"https:\/\/matrixbcg.com\/products\/globalcordbloodcorp-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}